Review outlines chemotherapy-related fatigue in breast cancer patients at high altitude

A review reports that chemotherapy-related fatigue affects an estimated 30–60% of breast cancer patients during treatment, with some experiencing persistent fatigue that can affect quality of life and prognosis. The article focuses on breast cancer patients in high-altitude regions, where hypoxia, low atmospheric pressure and temperature changes may contribute to the burden of fatigue. The evidence available here is limited to the review’s abstract, so its full methods, search strategy and detailed findings cannot be assessed.

The review describes chemotherapy-related fatigue as a multifactorial problem involving chronic inflammation, immune dysregulation, neuroendocrine abnormalities and mitochondrial dysfunction. According to the abstract, inflammation and immune readjustment are identified as primary factors, while high-altitude hypoxia may add to these processes. These mechanisms are presented as contributing factors rather than as results from a new clinical study, and the abstract does not provide study-specific estimates of how high altitude alters fatigue risk or severity.

For nonpharmacological management, the abstract reports evidence that physical activity, cognitive behavioral therapy and mindfulness have been effective in controlling fatigue. It also states that evidence for pharmacological treatment remains inconclusive. The authors emphasize that reversible factors, including anemia and sleep disorders, should be managed. This wording reflects the review’s summary of existing management evidence and does not establish that any intervention is effective specifically for patients living at high altitude.

The review calls for further research into chemotherapy-related fatigue mechanisms in elevated areas and for customized treatments intended to improve patients’ quality of life. That proposal is not a demonstrated outcome: the available evidence describes a review rather than a trial of altitude-specific treatment. The principal limitation is that only abstract-level information was supplied, preventing verification of the included studies, their populations, outcome measures, synthesis methods and certainty of conclusions. The review was published in Supportive Care in Cancer as Volume 34, article 903, on 28 August 2026.

Subject of Research: A review of chemotherapy-related fatigue mechanisms and management in breast cancer patients living at high altitude

Article Title: Recent advances in understanding chemotherapy-induced fatigue in BC patients residing in high-altitude regions: a review

Article References: Wu, T., Li, J., Zhao, F., & Liu, Z. (2026). Recent advances in understanding chemotherapy-induced fatigue in BC patients residing in high-altitude regions: a review. Supportive Care in Cancer, 34(9), Article 903. https://doi.org/10.1007/s00520-026-11151-6

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11151-6

Keywords: breast cancer, chemotherapy-related fatigue, high altitude, hypoxia, inflammation, immune dysregulation, quality of life, nonpharmacological care, supportive care, Recent, advances, understanding